A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.
Rift Valley fever virus (RVFV) has been cited as a potential biological-weapon threat due to the serious and fatal disease it causes in humans and animals and the fact that this mosquito-borne virus can be lethal in an aerosolized form. Current human and veterinary vaccines against RVFV, however, are outdated, inefficient, and unsafe. We have incorporated the RVFV glycoprotein genes into a nonreplicating complex adenovirus (CAdVax) vector platform to develop a novel RVFV vaccine. Mice vaccinated with the CAdVax-based vaccine produced potent humoral immune responses and were protected against lethal RVFV infection. Additionally, protection was elicited in mice despite preexisting immunity to the adenovirus vector.
GenPhar, Inc., Division of Biodefense Vaccines, 600 Seacoast Pkwy., Mount Pleasant, South Carolina 29464, USA.
David H
DH
Holman
Adam
A
Penn-Nicholson
Danher
D
Wang
Jan
J
Woraratanadharm
Mary-Katherine
MK
Harr
Min
M
Luo
Ellen M
EM
Maher
Michael R
MR
Holbrook
John Y
JY
Dong
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005822:Genetic Vectors; D008297:Male; D051379:Mice; D012295:Rift Valley Fever / Q000276:immunology / Q000517:prevention & control*; D012296:Rift Valley fever virus / Q000235:genetics / Q000276:immunology*; D016019:Survival Analysis; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000914:Antibodies, Viral; D015678:Viral Structural Proteins; D014765:Viral Vaccines